Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 18;11(4):863. doi: 10.3390/vaccines11040863

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Seroconversion and seroresponse after SARS-CoV-2 vaccination depicted as forest plots. (a) De novo seroconversion after the third and fourth vaccine dose stratified according to vaccine type and assay used to define seroconversion. (b) Total seroconversion (KTRs seropositive after last vaccine dose including previously seroconverted KTRs) after three and four vaccine doses. (c) Studies comparing de novo and total seroconversion in homologous (mRNA) and heterologous (mRNA/viral vector) vaccination strategies. (d) Variant-specific neutralization after three and four vaccine doses. (e) T-cell responses stratified according to assay after three and four vaccine doses. [20,22,23,25,26,27,28,29,31,32,33,34,37,39,40,41,42,43,44,46,47,48,49,51,54,55,56,57].